Difference between revisions of "Ciltacabtagene autoleucel (Carvykti)"
m |
m |
||
Line 14: | Line 14: | ||
==History of changes in Health Canada indication== | ==History of changes in Health Canada indication== | ||
*2023-02-09: Initial notice of compliance with conditions for the treatment of adult patients with [[multiple myeloma]], who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment. | *2023-02-09: Initial notice of compliance with conditions for the treatment of adult patients with [[multiple myeloma]], who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment. | ||
+ | ==History of changes in PMDA indication== | ||
+ | *2022-02-26: Initial approval | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' JNJ-68284528, LCAR-B38M | *'''Code names:''' JNJ-68284528, LCAR-B38M | ||
Line 31: | Line 33: | ||
[[Category:FDA approved in 2022]] | [[Category:FDA approved in 2022]] | ||
[[Category:Health Canada approved in 2023]] | [[Category:Health Canada approved in 2023]] | ||
+ | [[Category:PMDA approved in 2022]] |
Revision as of 20:36, 15 June 2023
Mechanism of action
From the NCI Drug Dictionary: A preparation of autologous T lymphocytes that are transduced, ex vivo, with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, the autologous bi-epitope BCMA-targeted CAR T cells JNJ-68284528 are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells.
Toxicity management
Diseases for which it is established (work in progress)
History of changes in FDA indication
- 2022-02-28: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody. (Based on CARTITUDE-1)
History of changes in EMA indication
- 2022-05-25: Initial conditional authorization
History of changes in Health Canada indication
- 2023-02-09: Initial notice of compliance with conditions for the treatment of adult patients with multiple myeloma, who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment.
History of changes in PMDA indication
- 2022-02-26: Initial approval
Also known as
- Code names: JNJ-68284528, LCAR-B38M
- Generic name: cilta-cel
- Brand name: Carvykti